TNDM · Tandem Diabetes Care Inc · Documents

Jun 18

Current report 8-K Events of May 22

Entered into a material agreement

May 23

Current report 8-K Events of May 22

Director or officer change, or executive pay, Shareholder vote results

May 16

Current report 8-K Events of May 10

Entered into a material agreement, Other events

May 2

Earnings call

Q1 2024 earnings call

May 2

Current report 8-K

Financial results

May 2

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $191.67M ▲ 13.2% Net loss $42.72M Diluted EPS -$0.65

Apr 9

Proxy statement DEF 14A

Proxy statement

Apr 9

Annual report to holders ARS

Annual report to holders

Apr 9

Proxy statement DEFA14A

Proxy statement

Apr 1

Current report 8-K Events of Mar 21

Other events

Mar 11

Current report 8-K Events of Mar 4

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Other events

Feb 21

Earnings call

Q4 2023 earnings call

Feb 21

Current report 8-K

Financial results

Feb 21

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $747.72M ▼ 6.7% Net loss $222.61M Diluted EPS -$3.43

Dec 11

Current report 8-K Events of Dec 5

Director or officer change, or executive pay

Nov 13

Current report 8-K Events of Nov 7

Director or officer change, or executive pay

Nov 6

Current report 8-K Events of Nov 3

Other events

Nov 1

Earnings call

Q3 2023 earnings call

Nov 1

Current report 8-K

Financial results

Nov 1

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $185.62M ▼ 9.3% Net loss $32.96M Diluted EPS -$0.51

Aug 18

Current report 8-K Events of Aug 17

Director or officer change, or executive pay

Aug 3

Earnings call

Q2 2023 earnings call

Aug 3

Current report 8-K

Financial results

Aug 3

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $195.92M ▼ 2.2% Net loss $35.78M Diluted EPS -$0.55

May 26

Current report 8-K Events of May 24

Shareholder vote results

May 3

Earnings call

Q1 2023 earnings call

May 3

Current report 8-K

Financial results

May 3

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $169.38M ▼ 3.7% Net loss $123.87M Diluted EPS -$1.92

Apr 12

Proxy statement DEF 14A

Proxy statement

Apr 12

Proxy statement DEFA14A

Proxy statement

Feb 22

Current report 8-K Events of Feb 17

Financial results, Director or officer change, or executive pay

Feb 22

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $801.22M ▲ 14.0% Net loss $94.59M Diluted EPS -$1.47

Jan 23

Current report 8-K Events of Jan 19

Completed an acquisition or sale of assets

Jan 10

Earnings call

Q4 2022 earnings call

Jan 10

Current report 8-K

Financial results

Dec 13

Current report 8-K Events of Dec 10

Entered into a material agreement

Nov 2

Earnings call

Q3 2022 earnings call

Nov 2

Current report 8-K

Financial results

Nov 2

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $204.55M ▲ 13.9% Net loss $48.97M Diluted EPS -$0.76

Aug 3

Earnings call

Q2 2022 earnings call

Aug 3

Current report 8-K

Financial results

Aug 3

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $200.26M ▲ 16.3% Net loss $15.06M Diluted EPS -$0.24

Jun 16

Current report 8-K Events of Jun 15

Director or officer change, or executive pay

May 27

Current report 8-K Events of May 25

Shareholder vote results

May 4

Earnings call

Q1 2022 earnings call

May 4

Current report 8-K

Financial results

May 4

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Revenue $175.91M ▲ 24.7% Net loss $14.72M Diluted EPS -$0.23

Apr 13

Proxy statement DEF 14A

Proxy statement

Apr 13

Proxy statement DEFA14A

Proxy statement

Mar 30

Proxy statement PRE 14A

Proxy statement